Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers by David, M. et al.
This is a repository copy of Identification of heparin-binding EGF-like growth factor 
(HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in 
human breast and prostate cancers.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/152904/
Version: Published Version
Article:
David, M., Sahay, D., Mege, F. et al. (5 more authors) (2014) Identification of 
heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid
receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS One, 9 (5). 
e97771. ISSN 1932-6203 
https://doi.org/10.1371/journal.pone.0097771
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Identification of Heparin-Binding EGF-Like Growth Factor
(HB-EGF) as a Biomarker for Lysophosphatidic Acid
Receptor Type 1 (LPA1) Activation in Human Breast and
Prostate Cancers
Marion David1,2, Debashish Sahay3,4,5, Florence Mege3,6, Franc¸oise Descotes7, Raphae¨l Leblanc3,4,5,
Johnny Ribeiro3,4,5, Philippe Cle´zardin3,4,5, Olivier Peyruchaud3,4,5*
1 INSERM, U1037, Toulouse, France, 2 Institut Claudius Re´gaud, Toulouse France, 3 INSERM, U1033, Lyon, France, 4Universite´ Claude Bernard Lyon 1, Villeurbanne, France,
5 Faculte´ de Me´decine Lyon Est, Lyon, France, 6Hoˆpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, 7Centre Hospitalier Lyon Sud, Hospices Civils de Lyon,
Pierre Be´nite, France
Abstract
Lysophosphatidic acid (LPA) is a natural bioactive lipid with growth factor-like functions due to activation of a series of six G
protein-coupled receptors (LPA1–6). LPA receptor type 1 (LPA1) signaling influences the pathophysiology of many diseases
including cancer, obesity, rheumatoid arthritis, as well as lung, liver and kidney fibrosis. Therefore, LPA1 is an attractive
therapeutic target. However, most mammalian cells co-express multiple LPA receptors whose co-activation impairs the
validation of target inhibition in patients because of missing LPA receptor-specific biomarkers. LPA1 is known to induce IL-6
and IL-8 secretion, as also do LPA2 and LPA3. In this work, we first determined the LPA induced early-gene expression profile
in three unrelated human cancer cell lines expressing different patterns of LPA receptors (PC3: LPA1,2,3,6; MDA-MB-231:
LPA1,2; MCF-7: LPA2,6). Among the set of genes upregulated by LPA only in LPA1-expressing cells, we validated by QPCR and
ELISA that upregulation of heparin-binding EGF-like growth factor (HB-EGF) was inhibited by LPA1–3 antagonists (Ki16425,
Debio0719). Upregulation and downregulation of HB-EGF mRNA was confirmed in vitro in human MDA-B02 breast cancer
cells stably overexpressing LPA1 (MDA-B02/LPA1) and downregulated for LPA1 (MDA-B02/shLPA1), respectively. At a clinical
level, we quantified the expression of LPA1 and HB-EGF by QPCR in primary tumors of a cohort of 234 breast cancer patients
and found a significantly higher expression of HB-EGF in breast tumors expressing high levels of LPA1. We also generated
human xenograph prostate tumors in mice injected with PC3 cells and found that a five-day treatment with Ki16425
significantly decreased both HB-EGF mRNA expression at the primary tumor site and circulating human HB-EGF
concentrations in serum. All together our results demonstrate that HB-EGF is a new and relevant biomarker with potentially
high value in quantifying LPA1 activation state in patients receiving anti-LPA1 therapies.
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Introduction
Lysophosphatidic acid (LPA) is a natural bioactive lipid involved
in multiple physiological processes [1–7]. LPA is a potent signaling
molecule with pleiotropic biological actions that through genomic
and/or nongenomic activities induces cell proliferation, survival,
motility, cytoskeletal rearrangement, and differentiation [8]. LPA
activates a series of six different G protein-coupled receptors (LPA
receptors [LPA1–6]) [9,10] that are distributed into two subfam-
ilies. LPA1, LPA2 and LPA3 form the Endothelial Differentiation
Gene (EDG) subfamily and LPA4, LPA5 and LPA6 form a
subfamily closely related to purinergic receptors. All LPA receptors
share intracellular signaling pathways dependent on heterotrimer-
ic G protein subtypes such as Gai (LPA1–4,6), Ga12/13 (LPA1–2,4–6),
Gaq (LPA1–5), and GaS (LPA4,6) [11,12] that upon activation
potentially lead to redundant, synergistic or even opposite effects
on cell biology. Most eukaryotic cells co-express multiple LPA
receptors. Therefore, pleiotropic activities of LPA are likely the
consequence of co-activation signals mediated by multiple
receptors.
LPA1 is the most ubiquitous of all LPA receptors in organs and
tissues both in human and mouse [13]. Lpar12/2 mice revealed
that LPA1 signaling influences the pathological process of many
diseases. These animals are partially protected against bleomycin-
induced lung fibrosis [14] and Lpar12/2 mice immunized with
type II collagen do not develop arthritis [15]. Additionally,
Lpar12/2 mice are resistant to neuropathic pain induced by partial
nerve ligation, and both allodynia and hyperalgesia induced in by
intrathecal injection of LPA is totally abolished in these animals
[16]. LPA1 is highly involved in cancer development. LPA1 has
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pro-oncogenic and pro-metastatic activities [17] and recent
developments of anti-LPA1 pharmacological drugs showed that
targeting this receptor is a therapeutic option for metastasis
suppression [18–20].
Therefore, LPA1 is an attractive target in multiple clinical
situations. However, current developments of LPA receptor
inhibitors are based on the use of LPA receptor-null cells, such
as the rat hepathoma RH7777 cells transfected to express
recombinant LPA receptor specific subtypes, and measuring the
capacity of the drugs inhibiting LPA-induced Ca2+ release in the
cytoplasm and GTPcS binding to the plasma membrane [21,22].
However, no specific LPA receptor biomarker has been defined so
far, which impairs validation of specificity and efficacy of these
drugs in more complex systems such as in cells expressing multiple
subtypes of LPA receptors, as well as in vivo both in animals and
humans. LPA1 was shown to induce the secretion of IL-6 and IL-8
in ovarian and breast cancer cells [23,24]. However, LPA2 and
LPA3 also induce the secretions of these cytokines [23,24]. Renal
cells from Lpar12/2 mice showed impaired expression of CTGF
indicating a close relationship between LPA1 activity and CTGF
expression [25]. However, TGF-b also controls CTGF expression
[26]. Thus, the specificity of CTGF expression through LPA1
activation requires further demonstration.
Here, we identified a set of genes specifically upregulated
through the activation of LPA1 based on transcriptomic analyses
of nongenetically manipulated tumor cells selected on the bases of
their different cancer of origin and on their distinct expression
panel of LPA receptors. Among those genes, we demonstrated in
vitro and in vivo that heparin-binding EGF-like growth factor (HB-
EGF) is a new specific biomarker for LPA1 activity in human
breast and prostate cancers. Our findings revealed that HB-EGF is
a potential new biomarker that will be useful to monitor the LPA1
activation state in patients receiving anti-LPA1 therapies.
Experimental Procedures
Ethic statement
The mice used in our study were handled according to the rules
of De´cret Nu 87–848 du 19/10/1987, Paris. The experimental
protocol was reviewed and approved by the Institutional Animal
Care and Use Committee of the Universite´ Claude Bernard Lyon-
1 (Lyon, France). Studies were routinely inspected by the attending
veterinarian to ensure continued compliance with the proposed
protocols. Male BALB/C nude mice, 4 weeks of age, were housed
under barrier conditions in laminar flow isolated hoods.
Autoclaved water and mouse chow were provided ad libitum.
Animals bearing tumor xenografts were carefully monitored for
established signs of distress and discomfort and were humanely
euthanized when these were confirmed. Studies involving human
primary breast tumors were performed according to the principles
embodied in the Declaration of Helsinki. Tissue biopsies were
obtained as part of surgical treatments for the hormone receptor
content determination. Remaining samples were included anon-
ymously in this study. All human experiments were approved by
the Experimental Review Board from the Laennec School of
Medicine that waived the need for consent.
Drugs and reagents
Lysophosphatidic acid (LPA, Oleoyl C18:1) was obtained from
Avanti Polar Lipids. The competitive inhibitors of LPA signaling
pathways dependent on LPA1 and LPA3 receptors, Ki16425 was
obtained from Cayman and Debio0719 was obtained from
Debiopharm SA.
Cell lines
Human cancer cell lines (MDA-MB-231, MCF-7 and PC3)
were obtained from the American Type Culture Collection.
Characteristics of MDA-B02/GFP-bGal breast cancer cells were
described previously [27]. Characteristics of MDA-B02/LPA1 and
MDA-B02/shLPA1 breast cancer cells were described previously
[18,28]. All cell lines were cultured in complete media, DMEM
medium (Invitrogen), 10% (v/v) fetal bovine serum (FBS, Perbio)
and 1% penicillin/streptomycin (Invitrogen), at 37uC in a 5%
CO2 incubator.
Reverse transcription and polymerase chain reaction
(RT-PCR)
Total RNA from cells and mouse xenograph tumors were
extracted using Nucleospin RNAII kit (Macherey-Nagel) and cDNA
were synthesized using iScript cDNA Synthesis kit (Biorad). The
cDNAs were amplified by PCR for 35 cycles consisting of 10 s of
denaturation at 95uC, 15 s of annealing at 67uC, and 10 s of extension
at 72uC with the following specific PCR primers: HB-EGF-F (59-
GGACCCATGTCTTCGGAAAT-39) and HB-EGF-R (59-CCC-
ATGACACCTCTCTCCAT-39) for HB-EGF; LPA1-F (59-TGG-
CATTAAAAATTTTACAAAAACA-39) and LPA1-R (59-AATAG-
TTACAACATGGGAATGG-39) for LPA1; LPA2-F (59-CGCTC-
AGCCTGGTCAAGACT-39) and LPA2-R (59-TTGCAGGACT-
CACAGCCTAAAC-39) for LPA2; LPA3-F (59-GGAGGACACC-
CATGAAGCTA-39) and LPA3-R (59-GGAACCACCTTTTCA-
CATGC-39) for LPA3; L32-F (59- CAAGGAGCTGGAAGT-
GCTGC-39) and L32-R (59- CAGCTCTTTCCACGATGGC-39)
for L32. Expression of mRNAs were quantified by real-time
quantitative RT-PCR in an Eppendorf Mastercycler RealPlex
(Invitrogen) using the SYBR Green PCR kit (Finnzymes). Quanti-
fications of target genes were normalized to corresponding L32 RNA
values.
Affymetrix analysis
Large-scale mRNA expression profiling was done on MDA-
MB-231, MCF-7 and PC3 cells untreated and treated with LPA
(1 mM) for 45 min. Total RNAs were purified as described above.
Labeled cRNA probes from two independent replicates were
hybridized to GeneChip Human Genome U1033 plus 2.0
(Affymetrix). Data were analyzed using Affymetyrix expression
console (v.1.1) software by ProfilExpert (Lyon, France). Mean
fluorescent signals of duplicated probe sets were calculated. All
probe sets with more than 1.3-fold increase in presence of LPA
defined LPA-dependent upregulated genes. The data discussed in
this publication have been deposited in NCBI’s Gene Expression
Omnibus [29] and are accessible through GEO Series accession
number GSE56265 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc =GSE56265).
Microarray correlation analysis
Publicly available gene expression data for Prostate Tumor
(GSE2109); Lung Tumor (GSE43580) and Colon Tumor
(GSE21510) were obtained. Log2 tranformed values for HB-
EGF and LPA1 expression were extracted from these database
using R2 genomics analysis and visualization platform. Scatter
plots were constructed. Analysis of correlation and computation of
linear regression of the data were performed using Prism v5.0b
(GraphPad Software, Inc.). P values ,0.05 were considered
significant.
HB-EGF as a LPA1 Activity Biomarker
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Patients and tumor characteristics
Patients were selected according to the following criteria:
primary breast tumor without inflammatory feature, no previous
treatment. Patients tumors were provide by three medical centers
(Centre Hospitalier Re´gional Annecy, Chirurgie Oncologique
Centre Hospitalier Universitaire Lyon-Sud, and Clinique Mutua-
liste Saint Etienne, France) in which patients were included
between October 1994 and October 2001. Breast cancer tissue
biopsies were obtained by surgery, selected by the pathologist and
immediately stored in liquid nitrogen until processing. The
biopsies were pulverized using a Mikro-Dismembrator (B. Braun
Biotech International, Melsungen, Germany) and total RNAs were
extracted using TRI Reagent (Sigma). To remove any genomic
DNA contamination, total RNAs were treated with RNAse-free
DNAse I and purified using RNeasy microcolumns (Qiagen).
Quality of RNAs was verified using an Agilent Bioanalyser 2100
(Agilent).
Animal studies
Tumor xenograph experiments were performed using PC3 cells.
Cells were suspended at a density of 106 cells in 100 ml of PBS and
inoculated subcutaneously into the flank of male BALB/C nude
mice at 4 weeks of age (Charles River). Tumor size was assessed by
external measurement of the length (L) and width (W) of the tumor
using a Vernier caliper. Tumor volume (TV; expressed in mm3)
was calculated using the following equation: TV= (LxW2)/2.
Thirty-five days post-tumor cell injection animals were treated
daily for 5 days with subcutaneous injection of Ki16425 (25 mg/
kg). Then animals were sacrificed. At that time the serum of each
animal was collected for human HB-EGF quantification by ELISA
(RayBiotech Inc) and PC3 xenograph tumors were submitted to
total RNA extraction as described above.
Statistical analysis
Data were analyzed with the GraphPad Prism v5.0c software.
Differences between groups were determined by one-way
ANOVA followed by Bonferroni post-test and single comparisons
were carried out using two-sided unpaired t-Test. Clinical multiple
group comparisons were performed using Kruskall-Wallis followed
Dunn’s post-test. P,0.05 was considered significant.
Results
Determination of LPA1-specific early genes upregulated
by LPA
LPA1 is the most ubiquitous LPA receptor in mammalian
tissues. As a consequence, its expression in cells and tissues is
frequently associated with other LPA receptors. Therefore, to
identify LPA1 activated genes independently of cell backgrounds
we defined a strategy based on the use of nongenetically modified
cell lines expressing different patterns of LPA receptors. In
addition, to avoid activation of cell type-specific genes we selected
the cell lines from two different human cancers of origin, breast
(MDA-MB-231 and MCF-7) and prostate (PC3). For breast cancer
cells we used two different types of cells, an estrogen positive cell
line (MCF-7) and a triple negative cell line (MDA-MB-231). Hama
and colleagues in 2004 showed that PC3 cells express LPA1, LPA2
and LPA3, MDA-MB-231 cells express at least LPA1 and LPA2,
and MCF-7 cells do not express LPA1 nor LPA3 but LPA2 [30].
These cells were subjected to total RNA extractions that were
labeled and cRNA were probed on Affimetrix GeneChip Human
Genome U1033 plus 2.0. In order to define the LPA receptor
expression profiles in each cell line, we first extracted the
fluorescent values obtained for each Affimetrix probe set
corresponding to LPA receptor genes (Figure 1A). Our results
confirmed that the cell lines used in our study expressed differently
LPA1, LPA2 and LPA3 receptors (Figure 1B). Moreover, we could
determine the complete LPA receptor patterns in PC3 cells (LPA1,
LPA2, LPA3 and LPA6), MDA-MB-231 cells (LPA1 and LPA2),
and MCF-7 cells (LPA2 and LPA6). This result indicated that
LPA2 was expressed in all three cell lines and that LPA1 was the
only receptor communally represented in PC3 and MDA-MB-231
cells (Figure 1B). Then we observed that LPA (1 mM) stimulation
for 45 min upregulated 253 probe sets in PC3 cells, 283 in MDA-
MB-231 cells, and 400 in MCF-7 cells and downregulated 465
probe sets in PC3 cells, 470 in MDA-MB-231 cells, and 332 in
MCF-7 cells (data not shown). Taking advantage that LPA1 was
expressed only in PC3 and MDA-MB-231 cells and not in MCF-7
cells, we identified a list of 74 distinct genes that were upregulated
downstream activation of LPA1-specific signaling pathways
(Figure 1C).
Expression of HB-EGF is mediated through functional
LPA1 in vitro
Among the 74 genes upregulated by LPA in a LPA1–dependent
manner, 9 genes were coding for secreted proteins: 2 matrix
proteins (COL27A1, COL6A1) and 7 cytokines and growth
factors [IL6, IL-8, CSF2(GM-CSF), DTR(HB-EGF),
CXCL1(Groa), CXCL2(Grob), CXCL3(Groc)]. Those genes
were good candidates for additional analyses because of the
potential use of their products as biomarkers detectable in
biological fluids. We have described previously in the context of
bone metastasis induced by breast cancer cells that LPA through
LPA1 controls the expression of IL6, IL-8, CSF2(GM-CSF), and
CXCL1(Groa) [18]. Here, we selected DTR coding for HB-EGF
for further investigation because links between LPA1 and HB-EGF
expression have not been described so far. We found that purified
LPA (1 mM) was as potent as FBS (10%) in upregulating HB-EGF
mRNA expression in PC3 cells after 45 min of stimulation
(Figure 2A). The effect of FBS was totally blocked when cells were
incubated in the presence of the LPA1–3 antagonist, Debio0719
[19]. This result was also observed in PC3 cells treated with
another LPA1–3 antagonist, Ki16425 [21] (Figure 2B). Moreover,
Ki16425 completely abolished FBS-induced expression of HB-
EGF in MDA-MB-231 cells (Figure 2B). These cells do not express
LPA3 (Figure 1A), supporting a prevalent role of LPA1 in HB-EGF
expression. To confirm the functional implication of LPA1 in HB-
EGF expression, we used three subclones of human MDA-B02
cells (MDA-B02/GFP-bGal, MDA-B02/LPA1, MDA-B02/
shLPA1) that we generated in previous studies [18,27,28,31].
We first validated by RT-QPCR the expression levels of LPA1 in
these cells. As expected, MDA-B02/GFP- b Gal cells express
LPA1 that is stably overexpressed in MDA-B02/LPA1 cells and
stably downregulated in MDA-B02/shLPA1 cells (Figure 2C).
RT-QCR analyses on these cells cultured in the presence of FBS
(10%) showed that expression of HB-EGF was significantly higher
in MDA-B02/LPA1 cells and lower in MDA-B02/shLPA1 cells
than in MDA-B02/GFP-bGal cells, respectively, confirming the
direct control of HB-EGF expression through LPA1 activation
(Figure 2D). We then tested the capacity of LPA to induce the
expression of HB-EGF after a more extended time of stimulation.
PC3 cells were treated for 24 h with LPA. Cells were harvested for
RNA extraction and mRNA quantifications, and culture media
were collected for secreted protein analysis. We observed that LPA
treatment upregulated the expression of HB-EGF mRNA
(Figure 2E) and the secretion of the protein (Figure 2F) by PC3
cells. Both LPA-induced upregulation of HB-EGF mRNA and
HB-EGF as a LPA1 Activity Biomarker
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protein secretion were totally inhibited in the presence of Ki16425
(Figures 2E, 2F).
Expression of HB-EGF correlates with LPA1 expression in
human primary tumors of breast, prostate, lung and
colon cancers
We then asked if the activity of LPA through LPA1 inducing
HB-EGF expression observed in our breast cancer cell lines could
be also observed in clinical human samples. We analyzed the
expression LPA1 and HB-EGF by real-time quantitative PCR in a
series of 234 primary tumor biopsies from patients with breast
cancer. We then distributed tumors form patients into four
quartiles according to the expression values of LPA1 (Q1, Q2, Q3,
Q4) and reported the mean relative expression value of HB-EGF
in each group. We observed that the LPA1-Q4 group, which has
the highest level of LPA1 expression, has a significantly higher
expression of HB-EGF than groups with lower expression of LPA1
(Q1 and Q2) (Figure 3A). We also observed that there was a
statistically significant positive correlation between LPA1 and HB-
EGF in these samples (Figure 3B). To further confirm our findings,
we then looked into publically available databases for Prostate
Tumor, Lung Tumor, and Colon Tumor. We observed that in the
prostate tumor database there was a moderate but highly
statistically significant positive correlation between LPA1 and
HB-EGF (Figure 3C). In addition, in lung and colon tumor
databases we observed a low but still highly statistically significant
Figure 1. Determination of LPA1-specific early genes upregulated by LPA. (A) Fluorescent values (Y-axis) of Affimetrix probe sets
corresponding to each LPA receptor (X-axis) generated using total RNAs isolated from PC3, MDA-MB-231 and MCF-7 cells. (B) Relative expression
levels of LPA receptors in PC3, MDA-MB-231 and MCF-7 cells extrapolated from Affimetrix fluorescent values presented in A). (C) Heat map of genes
significantly upregulated in both MDA-MB-231 (MDA-231) and PC3 cells and not in MCF-7 cells stimulated by LPA (1 mM) for 45 min. Color scale
corresponds to fold increase.
doi:10.1371/journal.pone.0097771.g001
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Figure 2. Expression of HB-EGF is mediated through functional LPA1 in vitro. (A,B,D,E) Expression of HB-EGF mRNA was measured by real-
time quantitative PCR and normalized to housekeeping L32 gene in (A) PC3 cells treated for 45 min with LPA (1 mM) or fetal bovine serum (FBS, 10%
w/v) in absence or presence of Debio0719 (Debio), (B) PC3 and MDA-MB-231 cells treated for 45 min with FBS (10% w/v) in absence or presence of
Ki16425 (10 mM), (D) MDA-B02/GFP-bGal, MDA-B02/shLPA1 and MDA-B02/LPA1 cells culture in presence of FBS 10%, and (E) PC3 cells treated for 24 h
HB-EGF as a LPA1 Activity Biomarker
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positive correlation between these two genes (Figure 3D and 3E).
Therefore, this result supports the hypothesis for a positive
correlation between LPA1 expression and HB-EGF expression in
vivo.
Pharmacological blockade of LPA1 in vivo inhibits HB-EGF
secretion by human PC3 xenographs
To confirm if LPA1 activity may control HB-EGF expression in
vivo, we generated xenograph tumors by subcutaneous injection of
with LPA (1 mM) in absence or presence of Ki16425 (10 mM). (C) Expression of LPA1 mRNA was measured by real-time quantitative PCR and
normalized to housekeeping L32 gene in MDA-B02/GFP-bGal, MDA-B02/shLPA1 and MDA-B02/LPA1 cells cultured in the presence of 10% FBS. (F)
Quantification of HB-EGF concentration in the conditioned culture media of PC3 cells treated for 24 h with LPA (1 mM) in absence or presence of
Ki16425 (10 mM). All values were the mean6SD of at least three experiments. *p,0.05; **p,0.01; ***p,0.001 using one-way ANOVA with a
Bonferroni post-test.
doi:10.1371/journal.pone.0097771.g002
Figure 3. Increased expression of HB-EGF linked to high expression of LPA1 in human primary tumors of breast, prostate, lung and
colon. (A) Total RNAs were extracted from 234 human primary breast tumor biopsies. Expression of LPA1 mRNA was measured by real-time
quantitative PCR and normalized to housekeeping L32 gene values. LPA1 relative expression values were distributed into quartiles (Q) dividing the
234 primary tumors into four equal groups with equal frequencies. HB-EGF relative expression values in each LPA1 subgroups were represented in
box plot. All values are the mean6SD of each quartile. *p,0.05; ***p,0.001 vs. Q4 using Kruskal-Wallis with Dunn’s post-test. (B) Scatter plot was
constructed showing the correlation between LPA1 and HB-EGF (R Spearman=0.25; p,0.0001) in the same RT-QPCR data. Scatter plots of LPA1 and
HB-EGF expression were constructed with the Log2 tranformed values extracted from publically available databases using R2 genomics analysis and
visualization platform for (C) Prostate Tumor (GSE2109; n = 72; R Spearman=0.45; p,0.0001); (D) Lung Tumor (GSE43580; n = 150; R Spearman= 0.29;
p,0.0001) and (E) Colon Tumor (GSE21510; n = 148; R Spearman= 0.27; p,0.0001).
doi:10.1371/journal.pone.0097771.g003
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PC3 cells in the right flank of male BALB/C nude mice. After 35
days, post-tumor cell injection animals were treated subcutane-
ously with Ki16425 (25 mg/kg) for 5 d. Animals were then
sacrificed. At that time, we collected the tumors for RNA
preparation and the serum of animals for protein quantification.
First, we found that a systemic treatment of animals for five days
with the LPA1 blocker did not alter tumor growth as judged by the
absence of difference in the volume of PC3 tumors in animals
treated with Ki16425 compared to vehicle-treated mice
(Figure 4A). This result was in agreement with previous reports
of our laboratory and others using breast cancer mouse models
[19,20]. We also found that Ki16425 treatment did not affect the
expression levels of LPA receptors in these tumors (Figure 4B).
However, we found that the level of HB-EGF mRNA was
significantly decreased by 28% in tumors of animals treated with
Ki16425 compared to tumors of animals treated with the vehicle
(p=0.0231; 0.016960.0011 vs. 0.0232760.0028) (Figure 4C).
Moreover, we observed that the concentration of human HB-EGF
was significantly decreased by 44% in the serum of animals treated
with Ki16425 compared to that of animals treated with the vehicle
(p=0.0321; 25.3563.14 vs. 44.9366.87) (Figure 4D). These
results indicate that blocking LPA1 activity in vivo inhibits the
expression and secretion of HB-EGF in animals bearing PC3
xenograph tumors.
Discussion
Studies using genetically modified cells and mice have revealed
the functional involvements of LPA1 in multiple pathological
processes. Overexpression of Lpar1 driven by the MMTV
promoter in the mammary gland of transgenic mice induces the
formation of spontaneous breast tumors within the first year [17].
Using immune compromised mice we showed that expression of
LPA1 confers a high propensity of inducing bone metastasis to
human breast cancer cells [18]. In that context, treatments with
the LPA1–3 antagonist Ki16425 inhibited the progression of
osteolytic bone metastases [18]. In addition, we recently described
that the LPA1–3 antagonist Debio0719 prevented spontaneous
metastasis dissemination of mouse 4T1 mammary cancer cells to
bone and lungs [19] with additional induction of tumor cell
Figure 4. Pharmacological blockade of LPA1 in vivo inhibits HB-EGF secretion by human PC3 xenographs. PC3 tumor cells were injected
subcutaneously in the right flank of male BALB/C nude mice. At day 35, post-tumor cell injection animals were randomized into two groups and
treated with Ki16425 (25 mg/kg) or the vehicle for 5 d. (A) Representative photographs of primary tumors at day 40 (upper panels). Box plot
represent tumor volumes (in mm3) (lower panels). Bar represents 10 mm. (B) LPAR1, LPAR2 and LPAR3 expressions were measured by real-time
quantitative PCR and normalized to housekeeping L32 gene values (Veh: Vehicle; Ki: Ki16425) (C) Box plot represents expression of HB-EGF mRNA
expression detected by real-time quantitative PCR from total RNAs isolated from tumors of animals treated with vehicle or Ki16425. Values were
normalized to housekeeping L32 gene. ": p,0.05, using unpaired Student t-Test. (D) Box plot represents HB-EGF concentration detected by ELISA in
the serum of animals treated with Ki16425 or vehicle. ": p,0.05, using unpaired Student t-Test.
doi:10.1371/journal.pone.0097771.g004
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dormancy at secondary sites [20]. However, validating that LPA1–
3 antagonists were inhibiting LPA1-specific pro-oncogenic and
pro-metastatic activities could not be achieved in these studies
because of missing LPA1-specific biomarkers.
Our transcriptomic analysis confirmed previous findings show-
ing that LPA induces the expression of the pro-osteoclastic
cytokines IL6 and IL8 through LPA1 in breast cancer cells [18,28].
The capacity of LPA1 in inducing the secretion of these cytokines
was further extended to ovarian cancer cells [23]. LPA1 shares this
activity with other LPA receptors as LPA3 also mediates both IL6
and IL8 expressions and LPA2 was identified to be the most
efficient receptor in linking LPA to IL-6 and IL-8 production in
ovarian cancer cells [24]. Therefore, IL6 and IL8 are unlikely
relevant LPA1-specific biomarkers. Among other cytokines, LPA
induces the expression of CYR61 and CTGF in epithelial cells
[25,32–34]. Analyses of Lpar12/2 animals or pharmacological
blockade of LPA receptors with Ki16425 revealed a major role of
LPA1 in LPA-induced CYR61 and CTG expressions in bacterial
infection and induction of tissue fibrosis in kidney and lungs
[25,32–34]. We observed that LPA induced the expression of both
CYR61 and CTGF in prostate and breast cancer cells (data not
shown). Expression of CYR61 and CTGF in MDA-MB-231 and
MCF-7 cells were previously reported, corroborating that expres-
sion of these two cytokines are not restrained to LPA1-expressing
cells [35]. CYR61 and CTGF genes are also upregulated by TGF-
b and commonly found in TGF-b gene signatures in different
cellular models [26,36,37]. Recent reports showed that LPA-
dependent expression of CTGF requires transactivation of TGF-b
receptor in myoblasts [38]. Thus, the specificity of CTGF
expression through LPA1 activation requires further demonstra-
tion. Based on cross-comparison analyses of whole genome
transcriptomic profiles of PC3, MDA-MB-231 and MCF-7 cells
in response to LPA, we determined a list of early genes
upregulated through LPA1 activation. In the perspective of
establishing a new biomarker easily accessible for sample
examination in clinic, we focused our study on the secreted
growth factor HB-EGF. We found that HB-EGF expression was
detected at an early time point following LPA stimulation (45 min).
Its expression was sustained at least up to 24 h of stimulation in vitro
and 5 d in vivo, suggesting the potential use of HB-EGF as a
relevant marker in the perspective of mid- to long-term follow-up.
Based on the quantification of HB-EGF in vitro, our results
demonstrated that the treatment of MDA-MB-231 breast and PC3
prostate cancer cells with LPA1–3 antagonists (Ki16425, De-
bio0719) mimicked Lpar1 gene silencing in MDA-B02 breast
cancer cells. Also, we found a significantly higher expression of
HB-EGF mRNA in human primary breast tumors that highly
expressed LPA1. Unfortunately, we were not able to confirm this
correlation at the protein level because biological samples from
patients of this cohort were not available. However, we were able
to quantify by ELISA the concentration of human HB-EGF
secreted by PC3 cells in the blood circulation of PC3 tumor-
bearing animals. Moreover, we validated that the pharmacological
blockade of LPA1 can be monitored in vivo through the inhibition
of HB-EGF expression both at mRNA levels in the primary
tumors and at protein levels in the blood circulation. LPA was
previously shown inducing the shedding of proHB-EGF in VeroH
cells through a Ras-Raf-MEK-dependent pathway [39]. LPA also
induces the shedding of proHB-EGF from the membrane of in
human bronchial epithelial cells involving activation of matrix
metalloproteinases leading to down-stream stimulation of EGFR
and the secretion of IL-8 [40]. However, these works did not
characterize which LPA receptor transmitted LPA signals. Our
results demonstrated at mRNA and protein levels that LPA
induces HB-EGF expression through an LPA1-dependent mech-
anism. Our study was based on manipulating breast and prostate
cancer cells and on analyzing publically available tumor databases
of breast, prostate, lung and colon cancers. Therefore, the
significance of HB-EGF as a biomarker of LPA1 activity in other
pathologies, such as tissue fibrosis [14,25], obesity [41], rheuma-
toid arthritis [15], osteoporosis [5], and neuropathic pain [42],
remains to be determined.
Disease-free and overall survivals are frequent primary end-
points validating drug efficacies in clinical trials. However, using
intermediate endpoints and biomarkers are required during the
course of therapies to validate drugs having reached their
dedicated targets. Our findings revealed that HB-EGF is a new
biomarker downstream stimulation of LPA1 that would be
extremely valuable to quantify the LPA1 activation state in
patients receiving anti-LPA1 therapies.
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